However, in practical practice, anti-IL-17 medications are exclusively used to treat psoriasis; anti-IL-17 therapies have not been approved for cancer treatment, most likely due to the pleiotropic effect of IL-17 and the intricate mechanisms of interaction with the TME. Here, IL17A is linked to cancer.